Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3% – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price shot up 20.3% during trading on Wednesday . The stock traded as high as $23.00 and last traded at $22.9850. 202 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 3,402 shares. The stock had previously closed at $19.11.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, BTIG Research began coverage on Ascentage Pharma Group International in a report on Thursday, March 12th. They set a “buy” rating and a $48.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The business’s 50-day moving average price is $24.33 and its two-hundred day moving average price is $30.11.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International in the second quarter worth $610,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the third quarter valued at about $96,000. ABC Arbitrage SA bought a new stake in Ascentage Pharma Group International during the third quarter worth about $204,000. Finally, UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.